Literature DB >> 34088999

The clinical pipeline for cancer cell therapies.

Samik Upadhaya, Jia Xin Yu, Monica Shah, Diego Correa, Tanya Partridge, Jay Campbell.   

Abstract

Entities:  

Year:  2021        PMID： 34088999     DOI： 10.1038/d41573-021-00100-z

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

1.  Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.

Authors:  Jiannan Chen; Jianhua Hu; Lili Gu; Feng Ji; Fan Zhang; Miaomiao Zhang; Jun Li; Zhengliang Chen; Longwei Jiang; Yan Zhang; Ruifang Shi; Lihua Ma; Shaochang Jia; Ying Zhang; Qi Zhang; Junqing Liang; Shunyu Yao; Zhigang Hu; Zhigang Guo
Journal:  Cancer Immunol Immunother       Date:  2022-08-04       Impact factor: 6.630

2.  Potential solutions for manufacture of CAR T cells in cancer immunotherapy.

Authors:  Ulrike Koehl; Stephan Fricke; Ulrich Blache; Georg Popp; Anna Dünkel
Journal:  Nat Commun       Date:  2022-09-05       Impact factor: 17.694

3.  A digital platform for the design of patient-centric supply chains.

Authors:  Niki Triantafyllou; Andrea Bernardi; Matthew Lakelin; Nilay Shah; Maria M Papathanasiou
Journal:  Sci Rep       Date:  2022-10-17       Impact factor: 4.996

4.  Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Authors:  Gyeyoung Choi; Gyeongseon Shin; SeungJin Bae
Journal:  Int J Environ Res Public Health       Date:  2022-09-28       Impact factor: 4.614
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.